All sponsors

PharmaEssentia

Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-33
RECRUITING0
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO80%

Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +17.6 months). See all sponsors →

Open PharmaEssentia on the live radar map →
TRIALPHASESTATUSCONDITIONNPRIMARY COMPLETION
Ropeginterferon alfa-2b
NCT05485948
P2Active, not recruitingPolycythemia Vera492022-09-07
SURPASS ET
NCT04285086
P3Active, not recruitingEssential Thrombocythemia1742024-11-12 (+33 mo)
Ropeginterferon alfa-2b-njft (P1101)
NCT05482971
P2Active, not recruitingEssential Thrombocythemia912025-05-09 (+9 mo)
P1101 (Ropeginterferon alfa-2b-njft)
NCT05481151
P3Active, not recruitingPolycythemia Vera1112025-06-30 (+18 mo)
Ropeginterferon alfa-2b
NCT06468033
P3Active, not recruitingPrimary Myelofibrosis; Myeloproliferative Neoplasm1602027-11-18 (+18 mo)